MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Cerebellar GABA-A receptor activity is inversely correlated with gait speed in Parkinson’s disease

    N.I. Bohnen, K.A. Frey, R.A. Koeppe, P.J.H. Scott, M.L.T.M. Muller (Ann Arbor, MI, USA)

    Objective: To investigate the relationship between regional cerebral expression of benzodiazepine receptors and gait speed in Parkinson's disease (PD). Background: Flumazenil is a short-acting intravenously…
  • 2016 International Congress

    The position of the conus medullaris and the prevalence of isolated lipoma of filum terminale in Parkinson’s disease

    H. Mori, K. Shindo (Kurashiki, Japan)

    Objective: To evaluate the positions of the conus medullaris in patients with Parkinson's disease(PD). To know the prevalence of isolated lipoma of filum terminale(LFT) in…
  • 2016 International Congress

    What predicts Parkinson’s disease? Hyposmia, MIBG SPECT, DAT SPECT and the PD-specific metabolic pattern

    S.K. Meles, D. Vadasz, R.J. Renken, K.M. Eggert, E. Sittig-Wiegand, C. Depboylu, V. Ries, G. Mayer, K. Reetz, S. Overeem, A. Pijpers, H. Höffken, M. Luster, K. Kesper, W. Oertel, K.L. Leenders (Groningen, Netherlands)

    Objective: To compare dopaminergic imaging, cardiac sympathetic denervation, olfactory function and expression of a PD-specific metabolic cerebral pattern in patients with idiopathic REM sleep behavior…
  • 2016 International Congress

    Detecting brainstem changes in Parkinson’s disease using quantitative MRI

    C. Lambert, A. Lutti, B. Draganski, T. Foltynie (London, United Kingdom)

    Objective: 1. Can brainstem changes be detected using quantitative MRI (qMRI). 2. How many subjects would be required to detecting changes in brainstem regions affected…
  • 2016 International Congress

    Substantia nigra hyperechogenicity in Mexican patients with Parkinson’s disease

    C.Y. Rodriguez-Garza, A. Anaya-Escamilla, R. Pinales-Razo, I. Estrada-Bellmann, C.R. Camara-Lemarroy (Monterrey, Mexico)

    Objective: To determine the prevalence of increased echogenicity in the substantia nigra in patients diagnosed with idiopathic Parkinson's disease at the University Hospital "Dr. José…
  • 2016 International Congress

    MMSE and MoCA feasibility in Parkinson’s disease and dementia with Lewy bodies: A multicenter 1-year follow-up study

    R. Biundo, L. Weis, S. Bostantjopoulou, E. Stefanova, C. Falup-Pecurariu, M.G. Kramberger, G. Geurtsen, A. Antonini, D. Weintraub, D. Aarsland (Venice, Italy)

    Objective: The aims of this study were to investigate which scale is best suited to assess cognition and more sensitive to cognitive decline over time…
  • 2016 International Congress

    Neuropsychological assessment in a cohort of patients with Parkinson’s disease

    C. Juri, W. Uslar, H. Farias, M. Vasquez (Santiago, Chile)

    Objective: To evaluate the cognitive profile in a cohort of patients with Parkinson's disease (PD) using a standardised battery. Background: Cognitive impairment is a great…
  • 2016 International Congress

    Cerebrospinal fluid biomarkers in Parkinson’s disease and associated cognitive impairment

    M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, J. Ruiz-Martínez, A. Bergaretxe-Yarza, J.F. Martí-Massó, P. Martínez-Lage, A. Izagirre, A. Oregi, L. Sepúlveda, M.C. Rodríguez-Oroz (San Sebastián, Spain)

    Objective: Our aim is to assess CSF levels of amyloid-β1-42 (Aβ1-42), T-Tau, threonine-181 phosphorilated tau (P-Tau) and α-synuclein (α-syn) as well as different ratios of…
  • 2016 International Congress

    How does cognition affect reaching in Parkinson’s disease?

    J. Cosgrove, C. Picardi, S.L. Smith, S. Jamieson, J.E. Alty (Leeds, United Kingdom)

    Objective: To explore differences in kinematic parameters of reach in those with Parkinson's disease (PD) classified into normal cognition (PD-NC), mild cognitive impairment (PD-MCI) and…
  • 2016 International Congress

    Longterm outcome of cognition following subthalamic deep brain stimulation in Parkinson´s disease

    D. Gruber, C. Lisa, A. Kuehn, U. Kopp, G.H. Schneider, A. Kupsch (Beelitz-Heilstätten, Germany)

    Objective: Longterm, “real-life” assessment of cognitive evolution following subthalamic (STN) deep brain stimulation (DBS) in patients suffering from Parkinson´s disease. Background: Anecdotal reports have speculated…
  • « Previous Page
  • 1
  • …
  • 123
  • 124
  • 125
  • 126
  • 127
  • …
  • 207
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley